Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

ACP-001

Other · developed by Ascendis Pharma

Phase 2 Most advanced trial (none active)

ASND Developer

3 Registered trials

What is ACP-001?

ACP-001 is a drug given by subcutaneous single-dose administration at several dose levels.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type: Other
Therapy area: Endocrine
Developer: Ascendis Pharma A/S (ASND)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 2
UNII: 5377795HRF

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT01947907	Phase 2	Growth Hormone Deficiency (GHD)	Completed	ASND
NCT01247675	Phase 2	Adult Growth Hormone Deficiency	Completed	ASND
NCT01010425	Phase 1	Healthy	Completed	ASND

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Adult Growth Hormone DeficiencyGrowth Hormone Deficiency (GHD)Healthy

More from Ascendis Pharma

Lonapegsomatropin FDA approved Navepegritide FDA approved Palopegteriparatide FDA approved TransCon CNP FDA approved Resiquimod Hydrogel-based Phase 1/2 TransCon hGH Phase 3 TransCon Treprostinil Phase 1

Sources

Updated Oct 11, 2026. Something wrong or missing? Report it on the ASND page.

Follow ASND, the company behind ACP-001

See ASND's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

ASND catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z